ユタにおける急性骨髄性白血病の臨床試験
ユタ内の拠点で、急性骨髄性白血病に関する17件の研究が参加者を募集しています。
ユタ内の都市
公式研究テキスト（英語）
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/28更新 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Intermountain Healthcare LDS Hospital, Salt Lake City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Primary Children's Hospital, Salt Lake City
被験者募集中第3相
6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- Huntsman Cancer Institute, Salt Lake City
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06824168(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Huntsman Cancer Institute - University of Utah Health, Salt Lake City
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT04996875A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- Huntsman Cancer Institute/University of Utah, Salt Lake City
被験者募集中第1相
18歳〜75歳 · 全性別 · 2026/08/25更新 · NCT05886049The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Primary Children's Hospital, Salt Lake City
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Primary Children's Hospital, Salt Lake City
被験者募集中第3相
29 Days – 21 Years · 全性別 · 2026/08/24更新 · NCT05183035A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Utah, Salt Lake City
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545Ivosidenib as Post-HSCT Maintenance for AML
- Huntsman Cancer Institute, University of Utah, Salt Lake City
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/06/18更新 · NCT06707493Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Utah, Salt Lake City
被験者募集中第1相
13歳以上 · 全性別 · 2026/05/05更新 · NCT04771572Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- University of Utah, Salt Lake City
被験者募集中第1相
21歳以下 · 全性別 · 2026/04/22更新 · NCT05101551A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/03/24更新 · NCT04988555ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。